Flavopiridol (Alvocidib) cadesine for 4 weeks) treatment results

for 4 weeks) treatment results in a more sustained pharmacodynamic inhibition of proteasome activity in tumors relative to normal tissues

AG-1517 rapidly suppresses autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocks EGF-mediated cellular processes including mitogenesis

Epub 2011 Mar 2

InChiKey: FSGCSTPOPBJYSX-VEIFNGETSA-N

Flavopiridol (Alvocidib) cadesine for 4 weeks) treatment resultsAlvocidib is a synthetic N methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin dependent kinases (CDKs) and by down regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity. Check for active clinical trials or closed clinical